Iontophoretic and chemical enhancement of drug delivery: Part I: Across artificial membranes

International Journal of Pharmaceutics

Volumn 257, Issue 1-2, 2003, Pages 41-55

  Nolan, L M A ^a,b   Corish, J ^a   Corrigan, O I ^a   Fitzpatrick, D ^a,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Hawkins House ^*  (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Buffer; Enhancers; Iontophoresis; Liquid crystals; Oleic acid; Salbutamol; Transdermal

Indexed keywords

BUFFER; DRUG VEHICLE; FATTY ACID; OLEIC ACID; SALBUTAMOL;

ARTICLE; ARTIFICIAL MEMBRANE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; FUNCTIONAL ASSESSMENT; ION EXCHANGE; IONTOPHORESIS; LIQUID CRYSTAL; MEASUREMENT; PRIORITY JOURNAL;

EID: 0037433815     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00108-X     Document Type: Article

References (43)

1. Abramson H., Gorin M.H. The electrophoretic demonstration of the patent pores of the living human skin: its relation to the change of the skin. J. Phys. Chem. 44:1940;1094-1102.
2. Allenby A.C., Fletcher J., Schock C., Tees T.F.S. The effect of heat, pH and organic solvents on the electrical impedance and permeability of excised human skin. Br. J. Dermatol. 4:1969;31.
3. Aungst B.J. Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharm. Res. 6:1989;244-247.
4. Aungst B.J., Blake J.A., Hussain M.A. Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm. Res. 7:1990;712-720.
5. Bannon, Y.B., 1989. A study of the transport processes governing passive and enhanced transdermal drug delivery. Ph.D. thesis, University of Dublin.
6. Bannon Y.B., Corish J., Corrigan O.I. Iontophoretic transport of model compounds from a gel matrix across an allophane membrane. Drug. Dev. Ind. Pharm. 13:1987;2617-2630.
7. Barry B.W. Lipid-protein-partitioning theory of skin penetration enhancement. J. Control. Release. 15:1991;237-248.
8. Barry, B.W., Williams, A.C., 1989. Human skin penetration enhancement: the synergy of propylene glycol with terpenes. In: Proceedings of the 16th International Symposium on Controlled Release of Bioactive Materials, CRS Inc., IL, USA.
9. + permeability of excised nude mouse skin. J. Pharm. Sci. 77:1988;492-497.
10. Burnette, R.R., 1989. In: Hadgraft, J., Guy, R.H. (Eds.), Transdermal Drug Delivery, Developmental Issues and Research Initiatives. Marcel Dekker, New York, p. 247.
11. Burnette R.R., Marrero D. Comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised mouse skin. J. Pharm. Sci. 75:1986;738-743.
12. Burrows R., Collett J.H., Attwood D. The release of drugs from monoglyceride-water liquid crystalline phases. Int. J. Pharm. 111:1994;283-293.
13. Carr M.G., Corish J., Corrigan O.I. Drug delivery from a liquid crystalline base across Visking and human stratum corneum. Int. J. Pharm. 157:1997;35-42.
14. Chien Y.W., Siddiqui Q., Shi W.-M., Lelawongs P., Liu J.-C. Direct current iontophoretic transdermal delivery of peptide and protein drugs. J. Pharm. Sci. 78:1989;376-383.
15. Cooper E.R. Increased skin permeability for lipophilic molecules. J. Pharm. Sci. 73:1984;1153-1158.
16. Corrigan O.I., Farver M.A., Higuchi W.I. Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) precipitates. Int. J. Pharm. 5:1980;229-238.
17. Degim I.T., Pugh W.J., Hadgraft J. Effect of ion complexants on the iontophoresis of salbutamol. Int. J. Pharm. 167:1998;229-231.
18. Engström S. Cubic phases as drug delivery systems. Polym. Preprints. 31:1990;157-158.
19. Ericsson, B., Erikson, P.O., Lofroth, J.E.R., Engström, S., 1991. Cubic phases as delivery systems for peptide drugs. In: Polymeric Drugs and Drug Delivery Systems. p. 251 (Chapter 22).
20. Francoeur M.L., Golden G.M., Russell O.P. Oleic acid: its effects on skin in relation to transdermal drug delivery. Pharm. Res. 7:1990;621-627.
21. Francoeur, M.L., Potts, R.O., 1990. European Patent, Pub. No. 0,435,436,A2, Paris.
22. Gay, C.L., Green, P.G., Guy, R.H., Francoeur, M.L., 1992. Iontophoretic delivery of piroxicam across the skin in vitro. In: Proceedings of the 19th International Symposium on Controlled Release of Bioactive Material, vol. 19. CRS Inc., IL, USA, pp. 242.
23. Goodman M., Barry B.W. Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique. Int. J. Pharm. 57:1989;29-40.
24. Guy R.H., Yogeshvar N.K., Delgado-Charro M.B., Merino V., Lopez A., Marro D. Iontophoresis: electrorepulsion and electroosmosis. J. Control. Release. 64:2000;129-132.
25. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int. J. Pharm. 184:1999;1-6.
26. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J. Soc. Cosmet. Chem. 11:1960;85-97.
27. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50:1961;874-875.
28. Higuchi T. Mechanism of sustained-action medication. J. Pharm. Sci. 52:1963;1145-1149.
29. Molyneux P., Frank H.P. The interaction of polyvinylpyrrolidone with aromatic compounds in aqueous solution. Part I: thermodynamics of the binding equilibria and interaction forces. J. Am. Chem. Soc. 83:1961;3169-3174.
30. Moser K., Kriwet K., Naik A., Kalia Y.N., Guy R.H. Passive skin penetration enhancement and its quantification in vitro. Eur. J. Pharm. Biopharm. 52:2001;103-112.
31. Murthy S.N., Rani S., Hiremath R. Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulphate. Drug Dev. Ind. Pharm. 27:2001;1057-1062.
32. Morimoto Y., Sugibayashi K., Kobayashi D., Shoji H., Yamazaki J., Kimura M. A new enhancer co-enhancer system to increase skin permeation of morphine hydrochloride in vitro. Int. J. Pharm. 91:1993;9-14.
33. Ordway R.W., Walsh J.V., Singer J.J. Arachidonic acid and other fatty acids directly activate potassium channels in smooth muscle cells. Science. 244:1989;1176-1179.
34. Padmanabhan, R.V., Surnham, J.M., 1991. Patent Corporation Treaty, WO 91/16077, A61K 74/21.
35. Phipps, J.B., Untereker, D.F., 1988. U.S. Patent 4,744,787.
36. Phipps J.B., Padmanabhan R.V., Lattin G.A. Iontophoretic delivery of model inorganic and drug ions. J. Pharm. Sci. 78:1989;365-369.
37. Spiegler K.S., Croyell C.D. Electromigration in cation exchange resin. II. Detailed analysis of two-component systems. J. Phys. Chem. 56:1952;106-113.
38. Su M.H., Srinivasan V., Ghanem A.H., Higuchi W.I. Quantitative in vivo iontophoretic studies. J. Pharm. Sci. 83:1994;12-17.
39. Swarbrick J., Siverly J.R. The influence of liquid crystalline gel phases on drug percutaneous absorption. II. Permeation studies through excised human skin. Pharm. Res. 9:1992;1550-1555.
40. Turunen T.M., Urtti A. Penetration enhancers in transdermal drug delivery. Acta Pharm. Fennica. 101:1992;3-10.
41. Tyle P. Iontophoretic devices for drug delivery. Pharm. Res. 3:1986;318-326.
42. + channels. J. Gen. Physiol. 98:1991;922-939.
43. Wieland S., Fletcher J.E., Gong Q.H. Differential modulation of a sodium conductance in skeletal muscle by intercellular and extracellular fatty acids. Am. J. Physiol. 263:1992;308-312.